Please Wait
Applying Filters...
menu
    • menu
    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    Data Compilation
    #PharmaFlow

    Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

    Stock Recap
    #PipelineProspector

    Menu

    LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS-1

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 152Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    04/06/2025 Arch Pharmalabs
    India
    		 ARCH PHARMALABS LTD 22162 NEVIRAPINE ANHYDROUS USP 2008-11-05 Inactive II N/A
    04/06/2025 Aurobindo Pharma Limited
    India
    		 APITORIA PHARMA PRIVATE LTD 17851 NEVIRAPINE ANHYDROUS USP 2004-11-16 Active II N/A